S&P 500   3,635.41 (+1.62%)
DOW   30,046.24 (+1.54%)
QQQ   294.47 (+1.41%)
AAPL   115.17 (+1.16%)
MSFT   213.86 (+1.78%)
FB   276.92 (+3.16%)
GOOGL   1,763.90 (+2.10%)
AMZN   3,118.06 (+0.63%)
TSLA   555.38 (+6.43%)
NVDA   518.31 (-1.39%)
BABA   279.96 (+3.65%)
CGC   26.97 (+9.10%)
GE   10.45 (+3.77%)
MU   63.95 (-0.36%)
AMD   85.07 (-0.28%)
T   29.23 (+2.13%)
NIO   53.51 (-3.38%)
F   9.45 (+6.66%)
ACB   9.23 (+28.55%)
NFLX   482.88 (+1.31%)
GILD   60.25 (+0.60%)
BA   218.49 (+3.29%)
DIS   151.49 (+3.77%)
S&P 500   3,635.41 (+1.62%)
DOW   30,046.24 (+1.54%)
QQQ   294.47 (+1.41%)
AAPL   115.17 (+1.16%)
MSFT   213.86 (+1.78%)
FB   276.92 (+3.16%)
GOOGL   1,763.90 (+2.10%)
AMZN   3,118.06 (+0.63%)
TSLA   555.38 (+6.43%)
NVDA   518.31 (-1.39%)
BABA   279.96 (+3.65%)
CGC   26.97 (+9.10%)
GE   10.45 (+3.77%)
MU   63.95 (-0.36%)
AMD   85.07 (-0.28%)
T   29.23 (+2.13%)
NIO   53.51 (-3.38%)
F   9.45 (+6.66%)
ACB   9.23 (+28.55%)
NFLX   482.88 (+1.31%)
GILD   60.25 (+0.60%)
BA   218.49 (+3.29%)
DIS   151.49 (+3.77%)
S&P 500   3,635.41 (+1.62%)
DOW   30,046.24 (+1.54%)
QQQ   294.47 (+1.41%)
AAPL   115.17 (+1.16%)
MSFT   213.86 (+1.78%)
FB   276.92 (+3.16%)
GOOGL   1,763.90 (+2.10%)
AMZN   3,118.06 (+0.63%)
TSLA   555.38 (+6.43%)
NVDA   518.31 (-1.39%)
BABA   279.96 (+3.65%)
CGC   26.97 (+9.10%)
GE   10.45 (+3.77%)
MU   63.95 (-0.36%)
AMD   85.07 (-0.28%)
T   29.23 (+2.13%)
NIO   53.51 (-3.38%)
F   9.45 (+6.66%)
ACB   9.23 (+28.55%)
NFLX   482.88 (+1.31%)
GILD   60.25 (+0.60%)
BA   218.49 (+3.29%)
DIS   151.49 (+3.77%)
S&P 500   3,635.41 (+1.62%)
DOW   30,046.24 (+1.54%)
QQQ   294.47 (+1.41%)
AAPL   115.17 (+1.16%)
MSFT   213.86 (+1.78%)
FB   276.92 (+3.16%)
GOOGL   1,763.90 (+2.10%)
AMZN   3,118.06 (+0.63%)
TSLA   555.38 (+6.43%)
NVDA   518.31 (-1.39%)
BABA   279.96 (+3.65%)
CGC   26.97 (+9.10%)
GE   10.45 (+3.77%)
MU   63.95 (-0.36%)
AMD   85.07 (-0.28%)
T   29.23 (+2.13%)
NIO   53.51 (-3.38%)
F   9.45 (+6.66%)
ACB   9.23 (+28.55%)
NFLX   482.88 (+1.31%)
GILD   60.25 (+0.60%)
BA   218.49 (+3.29%)
DIS   151.49 (+3.77%)
Log in
NASDAQ:PHAS

PhaseBio Pharmaceuticals Stock Forecast, Price & News

$3.57
-0.11 (-2.99 %)
(As of 11/24/2020 05:20 PM ET)
Add
Compare
Today's Range
$3.45
Now: $3.57
$3.71
50-Day Range
$2.73
MA: $3.36
$3.72
52-Week Range
$2.60
Now: $3.57
$8.49
Volume718,706 shs
Average Volume460,737 shs
Market Capitalization$104.83 million
P/E RatioN/A
Dividend YieldN/A
Beta1.62
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiopulmonary diseases. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.45 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PHAS
CUSIPN/A
CIKN/A
Phone(610) 981-6500
Employees40

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.36 million
Book Value$2.09 per share

Profitability

Net Income$-39,250,000.00
Net Margins-2,310.60%

Miscellaneous

Market Cap$104.83 million
Next Earnings Date3/29/2021 (Estimated)
OptionableNot Optionable
$3.57
-0.11 (-2.99 %)
(As of 11/24/2020 05:20 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PHAS News and Ratings via Email

Sign-up to receive the latest news and ratings for PHAS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











PhaseBio Pharmaceuticals (NASDAQ:PHAS) Frequently Asked Questions

How has PhaseBio Pharmaceuticals' stock price been impacted by Coronavirus?

PhaseBio Pharmaceuticals' stock was trading at $3.13 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PHAS shares have increased by 14.1% and is now trading at $3.57.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of PhaseBio Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PhaseBio Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for PhaseBio Pharmaceuticals
.

What stocks does MarketBeat like better than PhaseBio Pharmaceuticals?

Wall Street analysts have given PhaseBio Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but PhaseBio Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is PhaseBio Pharmaceuticals' next earnings date?

PhaseBio Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, March 29th 2021.
View our earnings forecast for PhaseBio Pharmaceuticals
.

How were PhaseBio Pharmaceuticals' earnings last quarter?

PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) released its earnings results on Thursday, November, 12th. The company reported ($0.86) EPS for the quarter, missing analysts' consensus estimates of ($0.77) by $0.09. PhaseBio Pharmaceuticals had a negative return on equity of 124.88% and a negative net margin of 2,310.60%.
View PhaseBio Pharmaceuticals' earnings history
.

What price target have analysts set for PHAS?

4 Wall Street analysts have issued twelve-month price objectives for PhaseBio Pharmaceuticals' shares. Their forecasts range from $10.00 to $18.00. On average, they anticipate PhaseBio Pharmaceuticals' stock price to reach $14.25 in the next year. This suggests a possible upside of 299.2% from the stock's current price.
View analysts' price targets for PhaseBio Pharmaceuticals
.

Who are some of PhaseBio Pharmaceuticals' key competitors?

What other stocks do shareholders of PhaseBio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PhaseBio Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Viking Therapeutics (VKTX), Selecta Biosciences (SELB), Sorrento Therapeutics (SRNE), Amarin (AMRN), Vaxart (VXRT) and Agile Therapeutics (AGRX).

Who are PhaseBio Pharmaceuticals' key executives?

PhaseBio Pharmaceuticals' management team includes the following people:
  • Jonathan P. Mow, Chief Executive Officer & Director
  • John P. Sharp, Chief Financial Officer
  • James Ballance, Vice President-Research & Scientific Affairs
  • John S. Lee, Chief Medical Officer
  • Kristopher L. Hanson, Secretary, Vice President & Head-Legal

When did PhaseBio Pharmaceuticals IPO?

(PHAS) raised $66 million in an initial public offering on Thursday, October 18th 2018. The company issued 5,000,000 shares at $12.50-$14.00 per share. Citigroup, Cowen and Stifel served as the underwriters for the IPO and Needham was co-manager.

What is PhaseBio Pharmaceuticals' stock symbol?

PhaseBio Pharmaceuticals trades on the NASDAQ under the ticker symbol "PHAS."

Who are PhaseBio Pharmaceuticals' major shareholders?

PhaseBio Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.87%), State Street Corp (1.02%), GSA Capital Partners LLP (0.53%) and Morgan Stanley (0.35%). Company insiders that own PhaseBio Pharmaceuticals stock include Clay Thorp, Glen Burkhardt, John P Sharp, Jonathan P Mow, Michael York and Nancy J Hutson.
View institutional ownership trends for PhaseBio Pharmaceuticals
.

Which institutional investors are selling PhaseBio Pharmaceuticals stock?

PHAS stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley.
View insider buying and selling activity for PhaseBio Pharmaceuticals
.

Which institutional investors are buying PhaseBio Pharmaceuticals stock?

PHAS stock was purchased by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, BlackRock Inc., and State Street Corp. Company insiders that have bought PhaseBio Pharmaceuticals stock in the last two years include Clay Thorp, John P Sharp, Jonathan P Mow, Michael York, and Nancy J Hutson.
View insider buying and selling activity for PhaseBio Pharmaceuticals
.

How do I buy shares of PhaseBio Pharmaceuticals?

Shares of PHAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is PhaseBio Pharmaceuticals' stock price today?

One share of PHAS stock can currently be purchased for approximately $3.57.

How big of a company is PhaseBio Pharmaceuticals?

PhaseBio Pharmaceuticals has a market capitalization of $104.83 million and generates $2.36 million in revenue each year. The company earns $-39,250,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis. PhaseBio Pharmaceuticals employs 40 workers across the globe.

What is PhaseBio Pharmaceuticals' official website?

The official website for PhaseBio Pharmaceuticals is www.phasebio.com.

How can I contact PhaseBio Pharmaceuticals?

PhaseBio Pharmaceuticals' mailing address is 1 Great Valley Parkway Suite 30, Malvern PA, 19355. The company can be reached via phone at (610) 981-6500 or via email at [email protected]

This page was last updated on 11/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.